We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.
We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.
We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.
We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.
We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.
We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.
We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.
We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.
We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.
We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.
We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.
We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.
We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.
We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.
We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.
We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.
We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.
We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.
We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.
We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.